Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
An estimated 21 million American women experience BV
The science leader comes with a rich experience in the employment testing industry
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Subscribe To Our Newsletter & Stay Updated
